论文部分内容阅读
目的观察口服匹伐他汀对高血压患者血清高敏C反应蛋白(hs-CRP)水平的影响。方法 60例高血压患者,随机分为对照组和匹伐他汀组,每组30例,分别单服用硝苯地平30 mg.d-1和服用匹伐他汀2 mg.d-1及硝苯地平30 mg.d-1,疗程为3 mo。观察治疗前和治疗3 mo后血压、血脂、血清hs-CRP和补体的变化。结果 2组患者用药3 mo后血压均明显下降(P<0.01),匹伐他汀组与对照组相比血压下降幅度有增大趋势,但无显著差异(P>0.05)。对照组患者治疗前后血脂各项指标无显著变化(P>0.05),匹伐他汀组治疗3 mo后总胆固醇、低密度脂蛋白胆固醇和三酰甘油水平较治疗前均明显降低(P<0.01),与对照组比较有显著差异(P<0.01)。2组治疗前后补体C3、C4水平无显著差异。治疗3 mo后对照组hs-CRP水平与治疗前相比无显著变化(P>0.05),匹伐他汀组hs-CRP水平较治疗前显著降低(P<0.05),与对照组相比差异显著(P<0.05)。结论匹伐他汀可以在调脂的同时降低高血压患者血清高敏C反应蛋白的水平。
Objective To observe the effect of oral pitavastatin on the serum hs-CRP level in patients with essential hypertension. Methods Sixty hypertensive patients were randomly divided into control group and pitavastatin group, 30 patients in each group were treated with nifedipine 30 mg.d-1 and pitavastatin 2 mg.d-1 and nifedipine 30 mg.d-1 for 3 months. Blood pressure, blood lipids, serum hs-CRP and complement levels before and 3 months after treatment were observed. Results The blood pressure was significantly decreased in both groups 3 months after treatment (P <0.01). Compared with the control group, the blood pressure of Pitavastatin group showed an increasing trend, but no significant difference (P> 0.05). The levels of total cholesterol, low density lipoprotein cholesterol and triglyceride in the pitavastatin group were significantly lower than those before treatment (P <0.01) after 3 months of treatment in the control group, , There was significant difference compared with the control group (P <0.01). There was no significant difference in levels of complement C3 and C4 between the two groups before and after treatment. The level of hs-CRP in the control group did not change significantly after 3 months of treatment (P> 0.05), while the hs-CRP level in the pitavastatin group was significantly lower than that before treatment (P <0.05), and the difference was significant compared with the control group (P <0.05). Conclusion Pitavastatin can reduce the level of serum high-sensitivity C-reactive protein in hypertensive patients while regulating lipid levels.